By Dan Primack
April 19, 2012

Human Genome Sciences (Nasdaq: HGSI) has rejected an unsolicited $2.59 billion takeover bid from GlaxoSmithKline, but did say that it will explore strategic alternatives that could include a sale of the company.

Johnson & Johnson
(NYSE: JNJ) has received European regulatory approval for its $21.3 billion acquisition of Swiss medical equipment maker Synthes Inc.

Primerica Inc. (NYSE: PRI) has agreed to repurchase around 5.74 million shares of common stock held by Warburg Pincus, for approximately $150 million. Warburg Pincus will still hold around 17.9% of Primerica’s common stock following the sale, or 23.2% including warrants.

Vodafone Group is the only remaining bidder for listed British network operator Cable & Wireless Worldwide PLC, after Tata Communications dropped out of the process, according to Bloomberg.

Want deal news in your inbox each morning? Get Term Sheet!

You May Like